Szela Mary T 4

What Happened

• Mary T. Szela, CEO, President and a director of TriSalus Life Sciences (TLSI), reported sales of restricted stock to cover tax withholding on vested RSUs. She sold 4,358 shares on 2026-03-11 at $4.13 each ($17,999) and 15,944 shares on 2026-03-17 at $3.85 each ($61,384), for a combined total of 20,302 shares and about $79,383. These were disposals (sales), not purchases.

Key Details

• Transaction dates and prices:
  • 2026-03-11: Sold 4,358 shares @ $4.13 = $17,999
  • 2026-03-17: Sold 15,944 shares @ $3.85 = $61,384
• Total shares sold: 20,302; total proceeds ≈ $79,383.
• Shares owned after transaction: Not specified in the excerpt; see the full Form 4 for the "Owned following reported transaction" amount.
• Footnote: F1 — These sales were made to satisfy tax withholding obligations related to the vesting of previously granted restricted stock units (RSUs). The filing notes this was not a discretionary sale by the reporting person.
• Filing: Form 4 filed with the SEC on 2026-03-20 reporting transactions dated Mar 11 and Mar 17, 2026. (Form 4s are generally required within two business days of the transaction; review the full filing for any timeliness flag.)

Context

• These sales are routine tax-withholding transactions tied to RSU vesting and are not presented as an expression of buy/sell sentiment by the insider. For retail investors, purchases typically carry more informational weight than routine, non-discretionary sales like tax-withholding disposals. See the full Form 4 for complete ownership details and any additional context.